MOLECULAR PROFILING IN LOW-GRADE EC 65 3 SUPPLEMENTARY eTable 1. Baseline characteristics of the four previous published studies and one submitted Van der Putten et al. 20161 Reijnen et al. 20192 Reijnen et al. 20203 Van Weelden et al. 20204 Reijnen et al. 20225 Study characteristics N included 265 42 28 28 30 Diagnostic classification based on Molecular profiling ProMisE ProMisE Molecular profiling Molecular profiling Median follow-up (months) 76.0 (0.0-197.0) 41.0 (14.0-87.0) 35.5 (0.0-197.0) 37.5 (3.0-21.0) 34.5 (3.0-168.0) Demographics European European Dutch European Dutch Patient characteristic Age (years) 63.0 (34.0-86.0) 66.0 (50.0-82.0) 57.0 (31.0-81.0) 66.0 (45.0-82.0) 67.0 (49.0-77.0) Primary treatment Lymph node dissection No 11 (4.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.3) Yes 254 (95.8) 42 (100.0) 28 (100.0) 24 (85.7) 28 (93.3) Pelvic 190 (74.8) 0 (0.0) 0 (0.0) 6 (25.0) 18 (64.3) Para-aortic 4 (1.6) 0 (0.0) 0 (0.0) 2 (8.3) 7 (25.0) Pelvic and para-aortic 45 (17.7) 0 (0.0) 0 (0.0) 9 (37.5) 3 (10.7) Unknown which nodes 15 (5.9) 42 (100.0) 28 (100.0) 7 (29.2) 0 (0.0) Unknown 0 (0.0) 0 (0.0) 0 (0.0) 4 (14.3) 1 (3.3) Final pathologic characteristics Histology EEC 26 (9.8) 42 (100.0) 20 (71.4) 17 (60.7) 0 (0.0) NEEC 239 (90.2) 0 (0.0) 8 (28.6) 11 (39.3) 30 (100.0) Grade 1-2 183 (69.1) 0 (0.0) 18 (64.3) 8 (28.6) 0 (0.0) 3 82 (30.9) 42.0 (100.0) 10 (35.7) 20 (71.4) 30 (100.0)
RkJQdWJsaXNoZXIy MTk4NDMw